Researchers combined advanced imaging techniques and theoretical physics to observe and explain how nanoclusters of the protein emerin form inside living cells. The study uncovers the molecular 'rules ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
GenAssist’s IND application for GEN6050X receives US FDA clearance, a globally first-in-class base editing drug for duchenne muscular dystrophy: Suzhou, China Friday, March 7, 2 ...
AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...
The growing occurrence of genetic disorders like sickle cell anemia, cystic fibrosis, and muscular dystrophy is fueling the demand for gene therapy and genome editing solutions, as these approaches ...
A new discovery about how tiny protein clusters form in cells could pave the way for treatments for Emery-Dreifuss muscular ...
Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...
A new discovery about how tiny protein clusters form in cells could pave the way for treatments for Emery-Dreifuss muscular dystrophy (EDMD), a rare genetic disorder that causes muscle weakness and ...
CRISPR technology offers innovative solutions for pandemic preparedness, enhancing diagnostics, antiviral therapies, and ...
Chimerix’s lead clinical pipeline candidate is dordaviprone, a first-in-class small molecule treatment designed to selectively target the mitochondrial protease ClpP and dopamine receptor D2 (DRD2).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback